Forbes Australia recognises Professor Mimi Tang as an entrepreneur to watch
Posted: 20 June 2024 Professor Mimi Tang, Scientific Founder and CEO, Prota Therapeutics has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen…
King’s Birthday Honours for contributions in research, education and public health
Posted: 14 June 2024 Victoria’s remarkable talent shines bright in this year’s King’s Birthday Honours, including nine leaders from BioMelbourne Network member organisations – AusBiotech,…
A$7M Placement Plus SPP to Advance Development and Commercialisation of Proprietary Research Tools, Diagnostics and Therapeutics
Posted: 13 June 2024 Highlights: INOVIQ successfully completed a A$7 million placement to institutional and sophisticated investors at A$0.50 per share. INOVIQ Board and Management have participated in the placement. Funds raised will be used to advance commercialisation…
Cartherics Secures Australian Patent for Innovative Cancer Cell Therapy
Posted: 12 June 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its first Australian patent, AU2016361451, entitled “Genetically…
ACPCC begins HPV self-collection campaign to providers
Posted: 4 June 2024 The Australian Centre for the Prevention of Cervical Cancer is pleased to announce that they have received government funding to undertake a nationwide healthcare provider education campaign about supporting patient choice in cervical…
Breakthrough exosome therapy to target and kill breast cancer
Posted: 4 June 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has successfully produced and isolated engineered exosomes (EEVs) that target and kill breast cancer cells in vitro. In a proof-of-concept study, a breast…
MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus
Posted: 4 June 2024 Murdoch Children’s Research Institute (MCRI) and Incepta Pharmaceuticals, based in Bangladesh, have embarked on a collaboration aimed at bringing life-saving innovation to the global healthcare landscape. MCRI has announced the signing of a non-exclusive licensing…
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
Posted: 4 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that it has entered into a clinical trial collaboration and…
Amplia establishes world class Clinical Advisory Board
Posted: 3 June 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce the appointment of five key opinion leaders and clinical oncologists to its Clinical Advisory Board (CAB). The CAB will provide expert…
DIMERIX AND TAIBA ENTER INTO AN EXCLUSIVE LICENSE AGREEMENT TO COMMERCIALISE DMX-200 IN THE MIDDLE EAST
Posted: 28 May 2024 Dimerix Limited (ASX: DXB, “Dimerix”) and Taiba Middle East FZ LLC, (“Taiba”), today announced that they have entered into an exclusive license agreement for the commercialisation of Dimerix’ Phase 3 drug candidate DMX-200 for…
Hydrix signs $2.3m contract with European medical technology company
Posted: 28 May 2024 Hydrix Limited (Hydrix or the Company) (ASX: HYD) is pleased to announce its wholly-owned subsidiary Hydrix Services has entered into a $2.3m contract with leading European medical company Paul Hartmann AG (Hartmann) (Contract). Under…
Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results
Posted: 28 May 2024 Starpharma (ASX: SPL, OTCQX: SPHRY), dedicated to helping patients with significant illnesses, such as cancer, achieve improved health outcomes through the application of our unique dendrimer technology, today announces the full results of the Phase…
